Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · EXAGEN INC. (XGN)

Exagen Q1 2026 revenue rises 12% to $17.3 million; net loss widens to $4.0 million

Mixed Impact 3 of 5 earnings Written later

Exagen reported first-quarter 2026 revenue of $17.3 million, up 12% from a year earlier, and reaffirmed full-year 2026 revenue guidance of $70 million to $73 million. The net loss widened to $3.97 million from $3.75 million, though the loss per share narrowed to $0.17 from $0.20 as the share count rose.

Key points

  • Revenue was $17.3 million, up from $15.5 million in the first quarter of 2025.
  • Net loss was $3.97 million, compared with $3.75 million a year earlier; net loss per share was $0.17 versus $0.20.
  • Full-year 2026 revenue guidance of $70 million to $73 million was maintained.
  • Cash and cash equivalents were $21.5 million at March 31, 2026, down from $32.2 million at December 31, 2025.

The filing

CompanyEXAGEN INC. (XGN)
Form8-K, current report
Filed with the SECMay 11, 2026, 8:03 AM ET
Accession number0001274737-26-000027

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.